Wu Xi STA, a subsidiary of Wuxi AppTec, and Coherent Biopharma, announced the signing of a strategic partnership agreement.
Under the agreement, WuXi STA will become the CDMO partner of choice and provide Coherent Biopharma with integrated CMC services to accelerate its current and future drug candidates, from API to pharmaceuticals, including but not limited to process development, manufacturing, testing. and file support regulations.
Building on the previous successful collaboration on CBP-1008, this strategic partnership between Coherent Biopharma and WuXi STA aims to expand the collaboration beyond CBP-1008. PDC drugs have wide applications, but development faces many technical challenges. WuXi STA has been deeply involved in the CDMO industry for over twenty years, with its leading capability for small molecules, peptides, high potency APIs, and complex conjugate such as PDC.
The WuXi STA Peptide Platform provides comprehensive CRDMO (Contract Research, Development and Manufacturing Organization) services from drug discovery to commercial manufacturing. The unique CRDMO peptide platform will provide Coherent Biopharma with flexible, high-quality solutions for all projects at different stages.
